Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study - Summary - MDSpire
Advertisement
Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study
To describe the clinical characteristics, outcomes, and potential risk factors associated with COVID-19 in patients with relapsed or refractory multiple myeloma (R/R-MM) who received BCMA-targeted CAR-T cell therapy during the Omicron wave.
Key Findings:
49 patients enrolled, median age 60 years, with a predominance of Durie-Salmon stage III.
93.9% experienced cytokine release syndrome (CRS) during CAR-T therapy, with 30.6% classified as severe CRS.
Overall response rate to CAR-T therapy was 98%, with 67.3% achieving complete remission.
Interpretation:
Patients with R/R-MM receiving BCMA-targeted CAR-T therapy are at high risk for severe COVID-19 due to immune dysfunction, highlighting the need for careful monitoring and management.
Limitations:
Retrospective design may introduce bias.
Limited sample size may affect generalizability of findings.
Conclusion:
The study underscores the vulnerability of BCMA-targeted CAR-T cell recipients to COVID-19 during the Omicron wave, necessitating enhanced protective measures and monitoring.
